Project Grant R01AG092390
Award Date
6/1/25
Completion Date
3/31/30
Dollars Obligated
$804K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94158, USA
Similar Awards
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $919,106 supports research to discover and optimize "APOE4 correctors" for the treatment of Alzheimer's disease. The award recipient, Sanford Burnham Prebys Medical Discovery Institute, will leverage advanced cellular assays, including a novel split nano-luciferase BITSA, to screen for small molecule compounds that can stabilize the APOE4 protein and make it functionally...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $431,750 to Arizona State University (ASU) to investigate the interaction between biological sex and the APOE genotype in modulating the risk of Alzheimer's disease onset and progression. The research will utilize human induced pluripotent stem cell lines with different APOE genotypes and sex chromosome complements to study how APOE and sex influence amyloid-beta processing, tau...
This Project Grant award for $564,530.00 was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to Emory University to investigate the role of the Alzheimer's disease risk gene APOE4 and the hormone follicle-stimulating hormone (FSH) in the development and progression of Alzheimer's disease, particularly in relation to gender-specific differences. The key objectives are to explore how APOE4 and FSH interact to facilitate Alzheimer's pathology, including through tau...
The National Institute on Aging (NIA) awarded a $341,000 Project Grant (CFDA 93.866 - Aging Research) to The Roskamp Institute, Inc., a non-profit biotechnology research organization in Sarasota, Florida. The grant, effective January 1, 2025 through December 31, 2026, will fund research to investigate the influence of the APOE4 genotype, a major genetic risk factor for Alzheimer's disease, on brain bioenergetics and the cerebrovasculature-astrocyte system. The research aims to examine how...
This $1,550,462 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports a 5-year multidisciplinary study to investigate the impact of Alzheimer's disease risk genes, with a focus on APOE E4, on brain function in a vulnerable population of HIV-positive older Black/African American adults. The study aims to enroll 120 HIV-positive participants aged 60-80 (60 with and 60 without the APOE E4 gene) and 80 demographically matched controls (40 with and...
This federal Project Grant award, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), is supporting research focused on optimizing and evaluating a brain-permeable CRISPR-based therapy for editing the APOE4 gene associated with Alzheimer's disease (AD). The $751,442 award to the University of California, Los Angeles (UCLA) aims to develop a synthetic exosome (SE)-encapsulated CRISPR system capable of crossing the blood-brain barrier and editing APOE4 to the less...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $3,281,385 to the University of California, San Diego (UCSD) to examine the role of specific phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions in existing Alzheimer's disease clinical trial datasets. The project aims to leverage 30 years of harmonized data from 14,602 participants across multiple clinical trials to...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,559,999 to the Regents of the University of Michigan to conduct a comprehensive study on the APOE gene and the noncoding RNA AANCR to advance Alzheimer's disease treatment. The research aims to elucidate how AANCR regulates APOE transcription and how AANCR is modulated to maintain cell-type specific and stress-induced APOE expression. The project will also assess the effects of APOE...
This $815,215 Project Grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) supports a comprehensive study on sex-based differences in Alzheimer's disease (AD) pathology and progression. The research aims to leverage neuroimaging techniques, plasma biomarkers, and tau PET imaging to investigate how sex and sex-based factors, such as reproductive period and APOE genotype, impact functional brain networks and the spread of tau pathology...